| umls-concept:C0038792 | skos:definition | MSH: A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.,NCI: A nonsteroidal anti-inflammatory drug (NSAID) that is being studied as a treatment for cancer.,PDQ: A sulfinylindene derivative prodrug with potential antineoplastic activity. Converted in vivo to an active metabolite, sulindac, a nonsteroidal anti-inflammatory drug (NSAID), blocks cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway; this inhibition permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41538&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx | lld:umls |
